GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
27 6월 2023 - 11:15PM
via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing human vaccines and immunotherapies
against infectious diseases and cancer, announced today the
publication of an article titled, “MVA-Vectored Universal
Beta-Coronavirus Vaccine Design & Development” in the June 2023
issue of the online journal Vaccine Insights. The
article is co-authored by GeoVax’s Chief Scientific Officer, Mark
Newman, PhD, together with other GeoVax scientists, Mary Hauser,
PhD, Arban Domi, PhD, Sreenivasa Oruganti, PhD, Pratima Kumari, PhD
and Ashley Zuniga, PhD and can be accessed here: Vaccine
Insights.
The article provides expert insight into the
emergence of SARS-CoV-2 (COVID-19), the risk of new “spillover
events” from animal hosts, and how this risk can be addressed
proactively. With regard to COVID-19 and its continually evolving
variants, the authors describe the limitations of first-generation
vaccines and the potential for MVA-vectored vaccines such as
GEO-CM04S1 to overcome these limitations.
About GEO-CM04S1
GEO-CM04S1 is a next-generation COVID-19 vaccine
based on GeoVax’s MVA viral vector platform, which supports the
presentation of multiple vaccine antigens to the immune system in a
single dose. CM04S1 presents both the spike and nucleocapsid
antigens of SARS-CoV-2 and is specifically designed to induce both
antibody and T cell responses to non-variable parts of the virus.
The more broadly specific and functional engagement of the immune
system is designed to protect against the new and continually
emerging variants of COVID-19. Based on data from animal models and
a completed Phase 1 clinical study, vaccine-induced immune
responses were shown to recognize both early and later variants of
SARS-CoV-2, including the Omicron variant. Vaccines of this format
should not require repeated modification and updating.
A recent presentation of unpublished data from the
open-label portion of the Phase 2 trial of CM04S1
(ClinicalTrials.gov Identifier: NCT04977024) in patients
undergoing hematological cancer treatment (i.e., patients who
have reduced immune system function as a result of treatment)
indicates that CM04S1 is highly immunogenic in these patients,
inducing both antibody responses, including neutralizing
antibodies, and T cell responses. These data support the planned
progression of the Phase 2 clinical study, which will include a
direct comparison to currently approved mRNA vaccines.
CM04S1 continues to advance in a second Phase 2
clinical trial as a booster for healthy patients who have
previously received the Pfizer or Moderna mRNA vaccine
(ClinicalTrials.gov Identifier: NCT04639466). Data from these
studies will form the basis for comparing vaccine potential in
unique patient groups as well as the general population.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing novel therapies and vaccines for
solid tumor cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in two
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a
COVID-19 vaccine for immunocompromised patients such as those
suffering from hematologic cancers and other patient populations
for whom the current authorized COVID-19 vaccines are insufficient.
In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating
the vaccine as a more robust, durable COVID-19 booster among
healthy patients who previously received the mRNA vaccines. GeoVax
has a leadership team who have driven significant value creation
across multiple life science companies over the past several
decades. For more information, visit our website:
www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our periodic reports on Form 10-Q and Form 10-K that
we have filed and will file with the SEC. Any forward-looking
statement made by us herein speaks only as of the date on which it
is made. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
Media Contact:Susan
Robertssr@roberts-communications.com202-779-0929
GeoVax Labs (NASDAQ:GOVXW)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GeoVax Labs (NASDAQ:GOVXW)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024